IPO Biotech company Bioversys plans to go public on the Swiss stock exchange

SDA

21.1.2025 - 11:43

Biotech Bioversys is another company that wants to be listed on the SIX Swiss Exchange. (archive picture)
Biotech Bioversys is another company that wants to be listed on the SIX Swiss Exchange. (archive picture)
Keystone

The Swiss stock exchange could become one biotech company richer in the course of the first quarter. The Basel-based company Bioversys is planning to go public, as detailed in a press release issued on Tuesday.

Keystone-SDA

The company is hoping to raise up to 80 million francs. The proceeds will primarily be used to finance a Phase III trial for the most important candidate, BV100. If the results are positive, the aim is to submit applications for approval to the most important health authorities by the end of 2027.

The Basel-based company focuses on the treatment of life-threatening infectious diseases. It concentrates on antibiotics. According to the information provided, BV100 is used to treat hospital infections with carbapenem-resistant Acinetobacter baumannii (CRAB). Alpibectir, on the other hand, is being developed by the Basel-based company in partnership with GSK for the treatment of tuberculosis (TB).

In addition to the approval-relevant study, the proceeds from the IPO are also intended to finance the company's operating costs and investment requirements from 2025 to 2028. In addition to BV100, the proceeds are also expected to support Alpibectir's ongoing Phase II development.

According to the press release, the two existing shareholders AMR Action Fund and GSK support the planned IPO. Both have expressed their intention to make further investments in the IPO following their previous equity investments.

The plan is to conduct the offering as a public offering in Switzerland and in the form of private placements in a number of jurisdictions, including the United States, to certain qualified institutional buyers.